Discover

DXCM
DexCom, Inc.
68.86
2 x 63.01
2 x 74.35
bid
ask
+
1.51
2.24%
2 @ 05:23 AM
69.15 +0.29 (0.42%)
Ytd3.75%
1y-17.61%
67.87
day range
69.66
54.11
52 week range
89.98
Open68.16Prev Close67.35Low67.87High69.66Mkt Cap26.57B
Vol4.75MAvg Vol5.65MEPS2.33P/E29.55Forward P/E22.34
Beta1.44Short Ratio2.40Inst. Own102.40%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2950-d Avg67.51200-d Avg67.161yr Est85.24

DXCM News

DexCom: The Growth Thesis Still Needs To Be Proven
seekingalpha.com
DexCom: The Growth Thesis Still Needs To Be Proven

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes mark

Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
zacks.com
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

benzinga.com
Deutsche Bank Initiates Coverage On DexCom with Buy Rating, Announces Price Target of $86

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

benzinga.com
Here's How Much You Would Have Made Owning DexCom Stock In The Last 20 Years

Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor
benzinga.com
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

benzinga.com
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $88

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

benzinga.com
FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

benzinga.com
TD Cowen Maintains Buy on DexCom, Raises Price Target to $95

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

benzinga.com
Mizuho Maintains Outperform on DexCom, Raises Price Target to $85

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
benzinga.com
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n

benzinga.com
Reported Saturday, Dexcom CONNECT Trial Shows G7 Delivers 1.6% Average A1C Reduction In Type 2 Diabe

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care

benzinga.com
Stifel Maintains Buy on DexCom, Raises Price Target to $90

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

benzinga.com
DexCom To Present New Data And Announce Strategic Business Initiatives At American Diabetes Associat

CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin